Make an inquiry

Refer a patient

Healthcare Professionals
Latest research
Publications
A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

20 Jan 2019

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.

Written by

Shore Neal D., MD, FACS

Mincik I, DeGuenther M, Student V Jr, Jievaltas M, Patockova J, Simpson K, Hu CH, Huang ST, Li Y, Lee Y, Chien B, Mao J.